Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 in Recurrent Glioblastoma
NCT00305656Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2006
- Primary completion
- Apr 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Jan 2006; status: completed.
02
Drugs
cediranib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00305656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305656.